Lee et al. [33] conducted a recent systemic review to assess the survival pattern of breast cancer patients with BRCA1 and BRCA2 mutations and found that the BRCA1-mutation carriers had a significantly decreased progression-free as well as overall survival compared to non-BRCA1-associated breast cancer patients, while BRCA2 mutations carriers had survival patterns comparable to the general breast cancer patients. This evidence concerns the gene BRCA2 and breast carcinoma.